Swiss hospital tests 'Double-Target' immune therapy for tough blood cancers
NCT ID NCT07166549
Summary
This early-stage trial is testing the safety of a new, locally-made CAR-T cell therapy designed to attack two targets (CD19 and CD20) on cancer cells. It is for adults with advanced B-cell leukemias or lymphomas who have relapsed after or cannot access standard treatments, including commercial CAR-T therapies. The main goal is to see if this two-target approach is safe and manageable for patients who have very few options left.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
University Hospital Basel, Division of Hematology or Medical Oncology
Basel, Canton of Basel-City, 4031, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.